Overview

This trial is active, not recruiting.

Condition age-related macular degeneration
Treatment triamcinolone acetonide
Phase phase 2/phase 3
Sponsor Canadian Retinal Trials Group
Collaborator University of British Columbia
Start date January 2004
End date March 2008
Trial size 120 participants
Trial identifier NCT00148551, 01 (C03 - 0236)

Summary

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

Measure
Changes in visual acuity from baseline.
time frame:

Secondary Outcomes

Measure
Change in lesion characteristics from baseline.
time frame:

Eligibility Criteria

Male or female participants at least 50 years old.

Inclusion Criteria: - Individuals with predominantly classic, subfoveal CNV secondary to AMD. - No previous PDT Treatment in study eye. Exclusion Criteria: - CNV from conditions, other than AMD. - Other disease that could be responsible for decreased vision.

Additional Information

Official title Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.
Description This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.
Trial information was received from ClinicalTrials.gov and was last updated in July 2007.
Information provided to ClinicalTrials.gov by Canadian Retinal Trials Group.